HR negative

Single-dye SLNB after NAT in patients initially diagnosed with cN1 breast cancer yielded a clinically acceptable FNR. When four or more SLNs were identified, an additional benefit was observed in patients who had a BMI <25 kg/m2 and negative estrogen receptor status.

P2, N=36, Not yet recruiting, Laura Huppert, MD, BA | Trial completion date: Mar 2029 --> Jun 2029 | Trial primary completion date: Mar 2029 --> Jun 2029

Molecular sub-types in endometrial cancer reflect distinct and reproducible phenotypes. However, classic histopathologic features remain the strongest predictors of nodal spread and SLN detection failure.

Because of this, early risk assessment and tailored imaging are crucial for timely diagnosis. This review defines high-risk factors for breast cancer, and the management of these individuals during pregnancy and lactation.

This study underscores that the management of suspected malignant transformation of adenomyosis requires multidisciplinary evaluation. More importantly, our findings demonstrate that aggressive treatment should be initiated even without definitive pathological confirmation when clinical suspicion is high. The significance of this work lies in its contribution to recognizing the heterogeneous nature of EC-AIA, urging future research to focus on elucidating molecular mechanisms and developing personalized therapeutic strategies for these aggressive variants.

HER2 expression levels (low/ultralow/null) stratify prognosis in HER2-negative eBC. The dynamic evolution of HER2 status following NAC and its prognostic utility highlights the importance of reassessing HER2 status in residual disease in HER2-negative eBC.

We report a 60-year-old woman with HER2-positive, hormone receptor-negative breast cancer who achieved pCR after neoadjuvant docetaxel combined with trastuzumab and pertuzumab, followed by 12 months of maintenance trastuzumab and pertuzumab. Emerging CNS-active therapies, including small-molecule tyrosine kinase inhibitors (TKIs) such as tucatinib and next-generation antibody-drug conjugates (ADCs) like trastuzumab deruxtecan, have shown promising intracranial activity. In addition, advanced strategies such as intensified MRI surveillance, radiomics, liquid biopsy, focused ultrasound-mediated BBB disruption, nanoparticle delivery systems, and radionuclide therapy offer potential avenues for early identification and prevention of cerebral metastases.

Adjuvant chemotherapy may optimize survival in select patients with T1b-T2N0M0 MBC, though prospective validation is warranted.

Ki67 appears to be an important prognostic biomarker in HR+ breast cancer across both HER2-low and HER2-positive subgroups. Dual stratification by HER2 and Ki67 status may improve risk assessment and help identify high-risk subgroups who could benefit from treatment approaches beyond endocrine therapy alone. These findings warrant confirmation in prospective studies.

P2, N=36, Recruiting, Laura Huppert, MD, BA | Not yet recruiting --> Recruiting

And small-tumor breast cancer patients do not usually benefit from AC. AC may not be recommended for certain subgroups, such as patients with pT1mi/a-bN0-1 HR+HER2- or pT1mi/a-bN0 HR-HER2-/HR+HER2+ can be exempted from chemotherapy.

The patient underwent a modified radical mastectomy followed by adjuvant chemotherapy and trastuzumab...This case highlights the diagnostic challenge of PCD, particularly when neurological manifestations precede tumor detection, and suggests that HER2-positive breast cancer may also be associated with anti-Yo antibodies. Early recognition of this syndrome and systematic malignancy screening are essential to improve patient outcomes.